BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 20230646)

  • 1. Genetic and epigenetic silencing of the beclin 1 gene in sporadic breast tumors.
    Li Z; Chen B; Wu Y; Jin F; Xia Y; Liu X
    BMC Cancer; 2010 Mar; 10():98. PubMed ID: 20230646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells.
    Rice JC; Massey-Brown KS; Futscher BW
    Oncogene; 1998 Oct; 17(14):1807-12. PubMed ID: 9778046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
    Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
    Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens.
    Rice JC; Ozcelik H; Maxeiner P; Andrulis I; Futscher BW
    Carcinogenesis; 2000 Sep; 21(9):1761-5. PubMed ID: 10964110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.
    Esteller M; Silva JM; Dominguez G; Bonilla F; Matias-Guiu X; Lerma E; Bussaglia E; Prat J; Harkes IC; Repasky EA; Gabrielson E; Schutte M; Baylin SB; Herman JG
    J Natl Cancer Inst; 2000 Apr; 92(7):564-9. PubMed ID: 10749912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.
    Borges S; Döppler H; Perez EA; Andorfer CA; Sun Z; Anastasiadis PZ; Thompson E; Geiger XJ; Storz P
    Breast Cancer Res; 2013 Aug; 15(2):R66. PubMed ID: 23971832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
    Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y
    Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping.
    Oldenburg RA; Kroeze-Jansema K; Meijers-Heijboer H; van Asperen CJ; Hoogerbrugge N; van Leeuwen I; Vasen HF; Cleton-Jansen AM; Kraan J; Houwing-Duistermaat JJ; Morreau H; Cornelisse CJ; Devilee P
    Clin Cancer Res; 2006 Mar; 12(6):1693-700. PubMed ID: 16551851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.
    Vos S; Moelans CB; van Diest PJ
    Breast Cancer Res; 2017 May; 19(1):64. PubMed ID: 28569220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UHRF1 is associated with epigenetic silencing of BRCA1 in sporadic breast cancer.
    Jin W; Chen L; Chen Y; Xu SG; Di GH; Yin WJ; Wu J; Shao ZM
    Breast Cancer Res Treat; 2010 Sep; 123(2):359-73. PubMed ID: 19943104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent CpG methylation of ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) in sporadic and hereditary Tunisian breast cancer patients: clinical significance.
    Trifa F; Karray-Chouayekh S; Jmaa ZB; Jmal E; Khabir A; Sellami-Boudawara T; Frikha M; Daoud J; Mokdad-Gargouri R
    Med Oncol; 2013 Mar; 30(1):418. PubMed ID: 23315218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of BRCA1 promoter methylation with rs11655505 (c.2265C>T) variants and decreased gene expression in sporadic breast cancer.
    Hasan TN; Leena Grace B; Shafi G; Syed R
    Clin Transl Oncol; 2013 Jul; 15(7):555-62. PubMed ID: 23263908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.
    Ward AK; Mellor P; Smith SE; Kendall S; Just NA; Vizeacoumar FS; Sarker S; Phillips Z; Alvi R; Saxena A; Vizeacoumar FJ; Carlsen SA; Anderson DH
    Breast Cancer Res; 2016 Jan; 18(1):12. PubMed ID: 26810754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyper-methylation of the upstream CpG island shore is a likely mechanism of GPER1 silencing in breast cancer cells.
    Manjegowda MC; Gupta PS; Limaye AM
    Gene; 2017 May; 614():65-73. PubMed ID: 28286086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1 Promoter Methylation and Clinicopathological Characteristics in Sporadic Breast Cancer Patients in Indonesia.
    Harahap WA; Sudji IR; Nindrea RD
    Asian Pac J Cancer Prev; 2018 Sep; 19(9):2643-2649. PubMed ID: 30256562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromosome band 17q21 in breast cancer: significant association between beclin 1 loss and HER2/NEU amplification.
    Negri T; Tarantino E; Orsenigo M; Reid JF; Gariboldi M; Zambetti M; Pierotti MA; Pilotti S
    Genes Chromosomes Cancer; 2010 Oct; 49(10):901-9. PubMed ID: 20589936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas.
    Swisher EM; Gonzalez RM; Taniguchi T; Garcia RL; Walsh T; Goff BA; Welcsh P
    Mol Cancer; 2009 Jul; 8():48. PubMed ID: 19602291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
    Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J
    Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis.
    Ramezani F; Salami S; Omrani MD; Maleki D
    Asian Pac J Cancer Prev; 2012; 13(2):451-7. PubMed ID: 22524805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers.
    Miyamoto K; Fukutomi T; Asada K; Wakazono K; Tsuda H; Asahara T; Sugimura T; Ushijima T
    Jpn J Clin Oncol; 2002 Mar; 32(3):79-84. PubMed ID: 11956301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.